Imaging of neuroendocrine prostatic carcinoma

Ahmed Taher; Corey T. Jensen; Sireesha Yedururi; Devaki Shilpa Surasi; Silvana C. Faria; Tharakeshwar K. Bathala; Bilal Mujtaba; Priya Bhosale; Nicolaus Wagner‐bartak; Ajaykumar C. Morani

doi:10.3390/cancers13225765

Imaging of neuroendocrine prostatic carcinoma

Ahmed Taher, Corey T. Jensen, Sireesha Yedururi, Devaki Shilpa Surasi, Silvana C. Faria, Tharakeshwar K. Bathala, Bilal Mujtaba, Priya Bhosale, Nicolaus Wagner‐bartak, Ajaykumar C. Morani

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that typically has a high metastatic potential and poor prognosis in comparison to the adenocarcinoma subtype. Although it can arise de novo, NEPC much more commonly occurs as a mechanism of treatment resistance during therapy for conventional prostatic adenocarcinoma, the latter is also termed as castration‐resistant prostate cancer (CRPC). The incidence of NEPC increases after hormonal therapy and they represent a challenge, both in the radiological and pathological diagnosis, as well as in the clinical management. This article provides a comprehensive imaging review of prostatic neuroendocrine tumors.

Original language	English (US)
Article number	5765
Journal	Cancers
Volume	13
Issue number	22
DOIs	https://doi.org/10.3390/cancers13225765
State	Published - Nov 1 2021

Keywords

Neuroendocrine
Prostate
Prostatic neuroendocrine carcinoma
Small cell carcinoma of prostate

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3390/cancers13225765

Cite this

@article{2084e39eb7604f429f1b2bb06f88e1ce,

title = "Imaging of neuroendocrine prostatic carcinoma",

abstract = "Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that typically has a high metastatic potential and poor prognosis in comparison to the adenocarcinoma subtype. Although it can arise de novo, NEPC much more commonly occurs as a mechanism of treatment resistance during therapy for conventional prostatic adenocarcinoma, the latter is also termed as castration‐resistant prostate cancer (CRPC). The incidence of NEPC increases after hormonal therapy and they represent a challenge, both in the radiological and pathological diagnosis, as well as in the clinical management. This article provides a comprehensive imaging review of prostatic neuroendocrine tumors.",

keywords = "Neuroendocrine, Prostate, Prostatic neuroendocrine carcinoma, Small cell carcinoma of prostate",

author = "Ahmed Taher and Jensen, {Corey T.} and Sireesha Yedururi and Surasi, {Devaki Shilpa} and Faria, {Silvana C.} and Bathala, {Tharakeshwar K.} and Bilal Mujtaba and Priya Bhosale and Nicolaus Wagner‐bartak and Morani, {Ajaykumar C.}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = nov,

day = "1",

doi = "10.3390/cancers13225765",

language = "English (US)",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "22",

}

TY - JOUR

T1 - Imaging of neuroendocrine prostatic carcinoma

AU - Taher, Ahmed

AU - Jensen, Corey T.

AU - Yedururi, Sireesha

AU - Surasi, Devaki Shilpa

AU - Faria, Silvana C.

AU - Bathala, Tharakeshwar K.

AU - Mujtaba, Bilal

AU - Bhosale, Priya

AU - Wagner‐bartak, Nicolaus

AU - Morani, Ajaykumar C.

PY - 2021/11/1

Y1 - 2021/11/1

N2 - Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that typically has a high metastatic potential and poor prognosis in comparison to the adenocarcinoma subtype. Although it can arise de novo, NEPC much more commonly occurs as a mechanism of treatment resistance during therapy for conventional prostatic adenocarcinoma, the latter is also termed as castration‐resistant prostate cancer (CRPC). The incidence of NEPC increases after hormonal therapy and they represent a challenge, both in the radiological and pathological diagnosis, as well as in the clinical management. This article provides a comprehensive imaging review of prostatic neuroendocrine tumors.

AB - Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that typically has a high metastatic potential and poor prognosis in comparison to the adenocarcinoma subtype. Although it can arise de novo, NEPC much more commonly occurs as a mechanism of treatment resistance during therapy for conventional prostatic adenocarcinoma, the latter is also termed as castration‐resistant prostate cancer (CRPC). The incidence of NEPC increases after hormonal therapy and they represent a challenge, both in the radiological and pathological diagnosis, as well as in the clinical management. This article provides a comprehensive imaging review of prostatic neuroendocrine tumors.

KW - Neuroendocrine

KW - Prostate

KW - Prostatic neuroendocrine carcinoma

KW - Small cell carcinoma of prostate

UR - http://www.scopus.com/inward/record.url?scp=85119149582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119149582&partnerID=8YFLogxK

U2 - 10.3390/cancers13225765

DO - 10.3390/cancers13225765

M3 - Review article

C2 - 34830919

AN - SCOPUS:85119149582

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 22

M1 - 5765

ER -

Imaging of neuroendocrine prostatic carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this